| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B A Berglund, D L Boring, G H Wilken, A Makriyannis, A C Howlett, S Li. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins, leukotrienes, and essential fatty acids. vol 59. issue 2. 1998-12-09. PMID:9774174. |
analogs of arachidonylethanolamide (anandamide) were prepared to investigate the structural requirements for ligand binding to and activation of the cb1 and cb2 cannabinoid receptors. |
1998-12-09 |
2023-08-12 |
Not clear |
| S Ben-Shabat, E Fride, T Sheskin, T Tamiri, M H Rhee, Z Vogel, T Bisogno, L De Petrocellis, V Di Marzo, R Mechoula. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European journal of pharmacology. vol 353. issue 1. 1998-10-29. PMID:9721036. |
2-arachidonoyl-glycerol (2-ara-gi) has been isolated from various tissues and identified as an endogenous ligand for both cannabinoid receptors, cb1 and cb2. |
1998-10-29 |
2023-08-12 |
mouse |
| S Ben-Shabat, E Fride, T Sheskin, T Tamiri, M H Rhee, Z Vogel, T Bisogno, L De Petrocellis, V Di Marzo, R Mechoula. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European journal of pharmacology. vol 353. issue 1. 1998-10-29. PMID:9721036. |
these two esters do not bind to the cannabinoid receptors, nor do they inhibit adenylyl cyclase via either cb1 or cb2; however, they significantly potentiate the apparent binding of 2-ara-gl and its apparent capacity to inhibit adenylyl cyclase. |
1998-10-29 |
2023-08-12 |
mouse |
| M H Rhee, M Bayewitch, T Avidor-Reiss, R Levy, Z Voge. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. Journal of neurochemistry. vol 71. issue 4. 1998-10-14. PMID:9751186. |
two cannabinoid receptors belonging to the superfamily of g protein-coupled membrane receptors have been identified and cloned: the neuronal cannabinoid receptor (cb1) and the peripheral cannabinoid receptor (cb2). |
1998-10-14 |
2023-08-12 |
Not clear |
| M H Rhee, M Bayewitch, T Avidor-Reiss, R Levy, Z Voge. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. Journal of neurochemistry. vol 71. issue 4. 1998-10-14. PMID:9751186. |
we found that independently of the method used to stimulate specific adenylyl cyclase isozymes (e.g., ionomycin, forskolin, constitutively active alpha(s), thyroid-stimulating hormone receptor activation), activation of the cannabinoid receptors cb1 and cb2 inhibited the activity of adenylyl cyclase types i, v, vi, and viii, whereas types ii, iv, and vii were stimulated by cannabinoid receptor activation. |
1998-10-14 |
2023-08-12 |
Not clear |
| S I Jaggar, F S Hasnie, S Sellaturay, A S Ric. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. vol 76. issue 1-2. 1998-10-13. PMID:9696473. |
the anti-hyperalgesic actions of the cannabinoid anandamide and the putative cb2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. |
1998-10-13 |
2023-08-12 |
rat |
| S I Jaggar, F S Hasnie, S Sellaturay, A S Ric. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. vol 76. issue 1-2. 1998-10-13. PMID:9696473. |
(1) the therapeutic effects of the cannabinoid anandamide and the putative cb2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder). |
1998-10-13 |
2023-08-12 |
rat |
| T W Klein, C Newton, H Friedma. Cannabinoid receptors and the cytokine network. Advances in experimental medicine and biology. vol 437. 1998-10-08. PMID:9666274. |
these results suggest that cannabinoids may increase th2 development and il-4 production in cultured immune cells through the activity of the cb2 receptor subtype. |
1998-10-08 |
2023-08-12 |
mouse |
| S J MacLennan, P H Reynen, J Kwan, D W Bonhau. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. British journal of pharmacology. vol 124. issue 4. 1998-10-02. PMID:9690851. |
evidence for inverse agonism of sr141716a at human recombinant cannabinoid cb1 and cb2 receptors. |
1998-10-02 |
2023-08-12 |
human |
| E Berdyshev, E Boichot, M Corbel, N Germain, V Lagent. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life sciences. vol 63. issue 8. 1998-09-03. PMID:9718090. |
these results demonstrate that the cannabinoid receptor ligands inhibited lps-induced pulmonary inflammation and suggest that this effect could be at least in part mediated by the cannabinoid cb2 receptor. |
1998-09-03 |
2023-08-12 |
mouse |
| N A Patel, R L Moldow, J A Patel, G Wu, S L Chan. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain research. vol 797. issue 2. 1998-08-06. PMID:9666136. |
it is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (aea), as well as exogenous cannabinoids such as delta9-tetrahydrocannabinol (thc), are mediated by two subtypes of cannabinoid receptors, cb1 and cb2, which have recently been characterized. |
1998-08-06 |
2023-08-12 |
rat |
| G van Zadelhoff, G A Veldink, J F Vliegenthar. With anandamide as substrate plant 5-lipoxygenases behave like 11-lipoxygenases. Biochemical and biophysical research communications. vol 248. issue 1. 1998-08-06. PMID:9675081. |
anandamide, an endogenous ligand for cannabinoid receptors cb1 and cb2, was incubated with purified 5-lipoxygenases from barley and tomato. |
1998-08-06 |
2023-08-12 |
Not clear |
| Q Tao, M E Aboo. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. The Journal of pharmacology and experimental therapeutics. vol 285. issue 2. 1998-06-08. PMID:9580609. |
mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, cb1 and cb2, disrupts g-protein coupling. |
1998-06-08 |
2023-08-12 |
Not clear |
| Q Tao, M E Aboo. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. The Journal of pharmacology and experimental therapeutics. vol 285. issue 2. 1998-06-08. PMID:9580609. |
the cannabinoid receptors, cb1 and cb2, are members of the g-protein coupled receptor family and share many of this family's structural features. |
1998-06-08 |
2023-08-12 |
Not clear |
| A C Herring, W S Koh, N E Kaminsk. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochemical pharmacology. vol 55. issue 7. 1998-06-08. PMID:9605425. |
the identification of two major types of g-protein-coupled cannabinoid receptors expressed on leukocytes, cb1 and cb2, has provided a putative mechanism of action for immune modulation by cannabinoid compounds. |
1998-06-08 |
2023-08-12 |
mouse |
| A C Herring, W S Koh, N E Kaminsk. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochemical pharmacology. vol 55. issue 7. 1998-06-08. PMID:9605425. |
collectively, these results demonstrate that cbn, a cannabinoid with minimal cns activity, inhibited both camp signal transduction and immune function, further supporting the involvement of cb2 receptors in immune modulation by cannabimimetic agents. |
1998-06-08 |
2023-08-12 |
mouse |
| J M Derocq, M Bouaboula, J Marchand, M Rinaldi-Carmona, M Ségui, P Casella. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS letters. vol 425. issue 3. 1998-05-13. PMID:9563506. |
the effect of anandamide, an endogenous ligand for central (cb1) and peripheral (cb2) cannabinoid receptors, was investigated on the growth of the murine il-6-dependent lymphoid cell line b9 and the murine il-3-dependent myeloblastic cell line fdc-p1. |
1998-05-13 |
2023-08-12 |
Not clear |
| J M Derocq, M Bouaboula, J Marchand, M Rinaldi-Carmona, M Ségui, P Casella. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS letters. vol 425. issue 3. 1998-05-13. PMID:9563506. |
comparison with other fatty acid cannabinoid ligands such as (r)-methanandamide, a ligand with improved selectivity for the cb1 receptor, or palmitylethanolamide, an endogenous ligand for the cb2 receptor, showed a very similar effect, suggesting that cell growth enhancement by anandamide or its analogs could be mediated through either receptor subtype. |
1998-05-13 |
2023-08-12 |
Not clear |
| D P Papahatjis, T Kourouli, V Abadji, A Goutopoulos, A Makriyanni. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols. Journal of medicinal chemistry. vol 41. issue 7. 1998-05-04. PMID:9544219. |
all the analogues tested showed nanomolar or subnanomolar affinities for the receptors; 2-(6a,7,10,10a-tetrahydro-6,6,9-trimethyl-1-hydroxy-6h- dibenzo[b,d]pyranyl)-2-hexyl-1,3-dithiolane was found to possess very high affinity for both cannabinoid receptors (cb1, ki = 0.32 nm; cb2, ki = 0.52 nm). |
1998-05-04 |
2023-08-12 |
Not clear |
| V V Bezuglov, Bobrov MYu, A V Archako. Bioactive amides of fatty acids. Biochemistry. Biokhimiia. vol 63. issue 1. 1998-04-28. PMID:9526091. |
ethanolamides of fatty acids are the most well-studied species of this group; an alternative pathway for their biosynthesis includes hydrolysis of n-acylated phosphatidylethanolamines by phospholipase d. ethanolamides of fatty acids bind to the cannabinoid receptors of the central nervous system (cb1) or peripheral tissues (cb2) and can be considered as endogenous ligands of these receptors. |
1998-04-28 |
2023-08-12 |
Not clear |